Rapid Viral Diagnostic Test by Digital Plasmonic Nanobubbles

利用数字等离子体纳米气泡进行快速病毒诊断测试

• 批准号: 10547200
• 负责人: Zhenpeng Qin
• 金额: $ 30万
• 依托单位: AVSANA LABS INCORPORATED
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-14 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10547200
• 关键词: Binding Proteins; Biological Assay; Biomedical Research; Biosensor; Categories; Chemistry; Clinic; Clinical; Clinical Sensitivity; Communicable Diseases; Complex; Consumption; Coupling; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic Equipment; Diagnostic tests; Dimensions; Early Diagnosis; Electronics; Engineering; Event; Future; Goals; Grant; Human; Immunoassay; In Vitro; Influenza; Laboratories; Lasers; Legal patent; Life; Measurement; Methods; Microfluidic Microchips; Molecular; Mucolytics; National Institute of Allergy and Infectious Disease; Nature; Optics; Performance; Phase; Physiologic pulse; Population; Preparation; Public Health; RNA; Rapid diagnostics; Research; Resource-limited setting; Respiratory syncytial virus; Risk; Sampling; Sensitivity and Specificity; Severities; Signal Transduction; Small Business Technology Transfer Research; Specificity; Specimen; System; Technology; Temperature; Test Result; Testing; Texas; Time; Universities; Validation; Viral; Virion; Virus; Virus Diseases; Work; antibody conjugate; base; cohort; commercialization; comorbidity; comparative; computerized data processing; coronavirus disease; cost; cost effective; design; detection platform; diagnostic platform; diagnostic value; digital; falls; in-vitro diagnostics; innovation; miniaturize; nanoGold; nanobubble; nanoparticle; nasopharyngeal swab; optical fiber; pandemic disease; particle; pathogen; pathogenic virus; plasmonics; point of care; point of care testing; point-of-care diagnostics; portability; prototype; rapid test; research and development; respiratory; respiratory virus; response; signal processing; success; vapor; viral detection

Project Summary/Abstract: Respiratory viruses are among the most serious threats to global public health, in part due to the limitations of currently commercially available tests: the high cost and time-consuming nature of lab-based tests, as well as the comparatively lower sensitivity and specificity of point-of-care (PoC) tests. There is a significant need for a rapid, portable, and inexpensive testing capability that is both highly sensitive and specific. The broad, long-term objective of this project is the development of a highly sensitive viral diagnostic test employing Avsana Labs’ digital plasmonic nanobubble (digital PNB) counting technology for detection of RSV, a globally significant virus selected for proof-of-concept studies. The viral test device implements sensing of virus particles by means of their attachment to antibody-conjugated gold nanoparticles, employing laser beams co-aligned in an optical fiber to generate nanobubbles from gold nanoparticles in a digital format (presence or absence of large nanobubbles) with the use of a microfluidic chip. The test will feature a rapid test turnaround time, high sensitivity and specificity, low cost, portability, and ease of use that will make it suitable for the PoC, including low-resource settings. Aim 1: Develop alpha-prototype platform for dPNB assay, demonstrating portability & functionality. In a related R01 study, the assay is realized using a laboratory setup. This aim will focus on miniaturizing optics and electronics from the lab setup into a benchtop-portable device as an alpha- prototype of a PoC platform, which would incorporate all the necessary signal processing around the detection mechanism, enabling a low-cost self-contained solution. Aim 2: Optimize the assay workflow and chemistry for intact RSV virus detection in clinical specimen matrix. The goal is to establish a robust assay workflow and chemistry to detect intact viruses in de-identified nasopharyngeal swab samples, in order to integrate with the alpha-prototype from Aim 1 and advance the technology toward a reliable diagnostic test for use in the clinic. Aim 3: Test the sensitivity and specificity of the dPNB assay with a pilot cohort of de-identified clinical containing RSV and Influenza type A specimens using the alpha-prototype. An important milestone towards commercialization is to establish early-on the ability to detect viruses in clinical specimens. We will test a small cohort of 60 de-identified clinical specimens, and use the original laboratory setup for reference. Societal benefits and broader impact on public health will be found in rapid and accurate in vitro viral pathogen diagnosis. Avsana envisions that the PNB platform will benefit the management of seasonal respiratory and emerging viral infections, and that additionally, it will accelerate the pandemic response and reduce the loss of lives in the likely event of future viral pandemics.

项目摘要/摘要：呼吸道病毒是全球公共卫生面临的最严重威胁之一